Aclaris Therapeutics, Inc.
ACRS
$1.75
-$0.06-3.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 22.13% | -84.20% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 22.13% | -84.20% | |||
| Cost of Revenue | 1.52% | -28.52% | |||
| Gross Profit | 1.06% | -27.74% | |||
| SG&A Expenses | -12.27% | 23.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.88% | -17.36% | |||
| Operating Income | 4.93% | -26.40% | |||
| Income Before Tax | -2.28% | 84.38% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.28% | 84.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.28% | 84.38% | |||
| EBIT | 4.93% | -26.40% | |||
| EBITDA | 4.93% | -26.58% | |||
| EPS Basic | -2.11% | 87.83% | |||
| Normalized Basic EPS | 5.96% | -5.15% | |||
| EPS Diluted | -2.11% | 87.84% | |||
| Normalized Diluted EPS | 5.96% | -5.15% | |||
| Average Basic Shares Outstanding | 0.16% | 28.42% | |||
| Average Diluted Shares Outstanding | 0.16% | 28.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||